managing toxicities in relapsed/refractory multiple myeloma: expert-led case discussions
Published 1 year ago • 216 plays • Length 1:02:56Download video MP4
Download video MP3
Similar videos
-
49:25
therapy of relapsed multiple myeloma - an update
-
42:24
elranatamab in relapsed or refractory multiple myeloma: the magnetismm-1 phase 1 trial
-
42:38
idh inhibitors in relapsed/refractory aml
-
1:29
managing toxicities associated with immunotherapy in multiple myeloma
-
56:37
management of multiple myeloma during covid 19
-
1:40
utilizing ai for individualized treatment-adjusted risk stratification in newly diagnosed myeloma
-
1:00:36
an update on new data of adcs for multiple myeloma
-
2:39
allogeneic therapy for the treatment of refractory hematological malignancies
-
1:01
car-t: myeloma toxicities
-
47:16
impact of a best practices program in patients with relapsed/refractory mm receiving selinexor
-
3:06
the role of artificial intelligence for precision medicine in multiple myeloma
-
37:23
predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
-
36:31
iach 2019: state-of-the-art management of multiple myeloma
-
0:56
long-term overall survival of aya patients with all who complete therapy on dfci consortium trials
-
1:01:58
novel agents in myeloma: different targets and mechanisms of action
-
54:09
nursing care at the era of modern therapy for multiple myeloma
-
52:12
the 1st online master class in transplantation and hematology (math) - session 1